https://www.nasdaq.com/press-release/aim-immunotechs-ampligen-safety-data-presented-at-eighth-european-scientific-working
https://www.nasdaq.com/press-release/aim-immunotech-ceo-to-participate-in-two-upcoming-investor-conferences-2021-12-06
https://www.nasdaq.com/press-release/aim-immunotech-provides-third-quarter-2021-business-update-2021-11-16-0
https://www.nasdaq.com/press-release/aim-immunotech-provides-third-quarter-2021-business-update-2021-11-16
https://www.nasdaq.com/press-release/aim-immunotech-submits-ind-and-accompanying-fast-track-application-for-phase-2-trial
https://www.nasdaq.com/press-release/aim-immunotech-submits-ind-and-accompanying-fast-track-application-for-phase-2-0
https://www.nasdaq.com/press-release/aim-immunotech-publishes-phase-1-clinical-study-data-supporting-the-safety-of
https://www.nasdaq.com/press-release/aim-immunotech-provides-clinical-updates-on-planned-phase-2-study-of-ampligen-in-0
https://www.nasdaq.com/press-release/aim-immunotech-provides-clinical-updates-on-planned-phase-2-study-of-ampligen-in
https://www.nasdaq.com/press-release/aim-immunotech-announces-clinical-trial-agreement-for-a-phase-2a-human-challenge-0
https://www.nasdaq.com/press-release/aim-immunotech-announces-clinical-trial-agreement-for-a-phase-2a-human-challenge
https://www.nasdaq.com/press-release/aim-immunotech-submits-pre-ind-application-to-the-fda-for-phase-2-clinical-studies-of
https://www.nasdaq.com/press-release/aim-immunotech-files-provisional-patent-application-for-ampligen-as-an-early-onset
https://www.nasdaq.com/press-release/aim-immunotech-announces-positive-progress-on-requested-fda-meeting-for-proposed
https://www.nasdaq.com/press-release/aim-immunotech-provides-an-update-on-its-pending-phase-2a-human-challenge-trial-using
https://www.nasdaq.com/press-release/aim-immunotech-submits-pre-ind-application-to-the-fda-for-phase-2-clinical-study-of
https://www.nasdaq.com/press-release/aim-immunotech-submits-pre-ind-application-to-the-fda-for-phase-2-clinical-study-of-0
https://www.nasdaq.com/press-release/aim-immunotech-announces-filing-of-provisional-patent-application-for-use-of-ampligen
https://www.nasdaq.com/press-release/aim-immunotech-provides-second-quarter-2021-business-update-2021-08-17
https://www.nasdaq.com/press-release/aim-immunotech-provides-second-quarter-2021-business-update-2021-08-17-0
https://www.nasdaq.com/press-release/aim-ceo-thomas-k.-equels-named-to-board-of-directors-of-bioflorida-inc.-2021-08-16
https://www.nasdaq.com/press-release/aim-immunotech-announces-phase-2a-human-challenge-trial-to-test-its-drug-ampligen-as
https://www.nasdaq.com/press-release/aim-immunotech-announces-phase-2a-human-challenge-trial-to-test-its-drug-ampligen-0
https://www.nasdaq.com/press-release/aim-immunotech-to-host-investor-update-webcast-on-wednesday-july-14th-at-11%3a00-am-et
https://www.nasdaq.com/press-release/aim-immunotech-completes-all-treatments-in-phase-1-human-safety-study-of-intranasal
https://www.nasdaq.com/press-release/aim-immunotechs-ampligen-featured-in-peer-reviewed-journal-cancers-as-a-potential
https://www.nasdaq.com/press-release/aim-immunotechs-ampligen-featured-in-peer-reviewed-journal-cancers-as-a-potential-0
https://www.nasdaq.com/press-release/aim-immunotech-announces-two-year-extension-of-agreement-with-shenzhen-smoore
https://www.nasdaq.com/press-release/aim-immunotech-announces-positive-safety-data-from-the-third-cohort-of-its-phase-1
https://www.nasdaq.com/press-release/aim-immunotech-provides-first-quarter-2021-business-update-2021-05-18
https://www.nasdaq.com/press-release/aim-immunotech-ceo-thomas-k.-equels-participates-in-fireside-chat-with-ascendiant
https://www.nasdaq.com/press-release/aim-immunotech-announces-positive-safety-data-in-second-cohort-of-phase-1-clinical
https://www.nasdaq.com/press-release/aim-immunotech-announces-positive-safety-data-in-first-cohort-of-phase-1-clinical
https://www.nasdaq.com/press-release/aim-immunotech-announces-positive-safety-data-in-first-cohort-of-phase-1-clinical-0
https://www.nasdaq.com/press-release/aim-immunotech-reports-2020-year-end-financial-results-2021-03-31
https://www.nasdaq.com/press-release/aim-immunotech-announces-addition-of-single-agent-ampligen-arm-to-cancer-centers
https://www.nasdaq.com/press-release/aim-immunotech-to-present-at-the-q1-virtual-investor-summit-on-march-24th-2021-03-11
https://www.nasdaq.com/press-release/aim-immunotech-to-participate-at-m-vest-llc-and-maxim-group-llc-inaugural-emerging
https://www.nasdaq.com/press-release/aim-immunotech-announces-first-healthy-subjects-dosed-in-phase-1-intranasal-0
https://www.nasdaq.com/press-release/aim-immunotech-announces-first-healthy-subjects-dosed-in-phase-1-intranasal-ampligen
https://www.nasdaq.com/press-release/aim-immunotech-to-present-at-the-h.c.-wainwright-global-life-sciences-conference-on
https://www.nasdaq.com/press-release/aim-immunotechs-subsidiary-receives-orphan-medicinal-product-designation-by-the-0
https://www.nasdaq.com/press-release/aim-immunotechs-subsidiary-receives-orphan-medicinal-product-designation-by-the
https://www.nasdaq.com/press-release/aim-immunotech-announces-ethics-committee-approval-to-commence-phase-1-clinical-0
https://www.nasdaq.com/press-release/aim-immunotech-announces-ethics-committee-approval-to-commence-phase-1-clinical-study
https://www.nasdaq.com/press-release/aim-immunotech-announces-the-expansion-of-its-pancreatic-cancer-program-to-include
https://www.nasdaq.com/press-release/aim-immunotech-announces-the-expansion-of-its-pancreatic-cancer-program-to-include-0
https://www.nasdaq.com/press-release/aim-immunotech-completes-and-closes-atm-facility-current-capital-expected-to-meet
https://www.nasdaq.com/press-release/aim-immunotech-completes-and-closes-atm-facility-current-capital-expected-to-meet-0
https://www.nasdaq.com/press-release/aim-immunotech-enters-into-agreement-for-proposed-intranasal-safety-study-of-ampligen
https://www.nasdaq.com/press-release/aim-immunotech-reschedules-investor-conference-call-to-january-21-2021-at-11am-et
https://www.nasdaq.com/press-release/aim-immunotech-postpones-investor-conference-call.-will-reschedule-for-a-later-date
https://www.nasdaq.com/press-release/aim-immunotech-announces-first-covid-19-induced-chronic-fatigue-long-hauler-patient
https://www.nasdaq.com/press-release/aim-immunotech-announces-availability-of-the-me-cfs-clinical-trial-of-its-drug-0
https://www.nasdaq.com/press-release/aim-immunotech-announces-availability-of-the-me-cfs-clinical-trial-of-its-drug
https://www.nasdaq.com/press-release/aim-immunotech-inc.s-drug-ampligen-awarded-fdas-orphan-drug-designation-status-for-0
https://www.nasdaq.com/press-release/aim-immunotech-inc.s-drug-ampligen-awarded-fdas-orphan-drug-designation-status-for
https://www.nasdaq.com/press-release/aim-announces-milestone-in-covid-19-treatment-and-prevention-efforts-with-first-0
https://www.nasdaq.com/press-release/aim-announces-milestone-in-covid-19-treatment-and-prevention-efforts-with-first
https://www.nasdaq.com/press-release/aim-immunotech-provides-third-quarter-2020-business-update-2020-11-13
https://www.nasdaq.com/press-release/aim-immunotech-announces-plos-ones-publication-of-new-data-analyses-showing
https://www.nasdaq.com/press-release/bioflorida-names-aim-immunotech-ceo-thomas-k.-equels-as-entrepreneur-of-the-year-2020
https://www.nasdaq.com/press-release/aim-immunotech-ceo-to-participate-in-virtual-panel-presentation-at-the-23rd-annual
https://www.nasdaq.com/press-release/aim-immunotech-announces-irb-approval-to-enroll-covid-19-long-haulers-in-the-amp-511
https://www.nasdaq.com/press-release/aim-immunotech-receives-statistically-significant-positive-survival-results-in
https://www.nasdaq.com/press-release/aim-immunotech-highlights-start-of-recruitment-in-roswell-park-clinical-trial
https://www.nasdaq.com/press-release/aim-immunotech-to-present-at-the-h.c.-wainwright-22nd-annual-global-investment
https://www.nasdaq.com/press-release/aim-immunotech-ceo-to-participate-in-virtual-panel%3a-new-approaches-to-covid-19%3a
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/aim-immunotech-inc.-decreases-sars-cov-2-infectious-viral-yields-by-90-using-new-in
https://www.nasdaq.com/press-release/aim-immunotech-to-present-at-the-ld-500-virtual-conference-on-september-1st-2020-08
https://www.nasdaq.com/press-release/aim-immunotech-provides-second-quarter-2020-business-update-and-reports-progress-in
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/49-public-companies-to-present-at-the-snn-network-virtual-conference-on-august-3-6
https://www.nasdaq.com/press-release/aim-immunotech-to-present-at-the-snn-network-virtual-investor-conference-on-monday
https://www.nasdaq.com/press-release/aim-immunotech-signs-clinical-trial-agreement-with-roswell-park-comprehensive-cancer
https://www.nasdaq.com/press-release/aim-immunotech-signs-material-transfer-and-research-agreement-with-japans-national
https://www.nasdaq.com/press-release/aim-immunotech-added-to-russell-microcapr-index-2020-06-29
https://www.nasdaq.com/press-release/aim-immunotech-provides-update-on-commercial-launch-of-ampligenr-in-argentina-for-the
https://www.nasdaq.com/press-release/aim-immunotech-files-provisional-patent-application-for-the-use-of-ampligenr-as-a
https://www.nasdaq.com/press-release/aim-immunotech-announces-fda-authorization-for-first-human-ampligen-trial-in-covid-19
https://www.nasdaq.com/press-release/aim-immunotechs-ceo-to-present-at-maxims-infectious-disease-virtual-conference-2020
https://www.nasdaq.com/press-release/aim-immunotechs-ceo-to-present-at-the-planet-microcap-showcase-virtual-investor
https://www.nasdaq.com/press-release/aim-immunotech-and-shenzhen-smoore-technology-announce-an-agreement-to-research
https://www.nasdaq.com/press-release/aim-immunotech-announces-the-national-cancer-institutes-award-of-%2414.54m-to-study
https://www.nasdaq.com/press-release/aim-immunotech-reports-2019-year-end-financial-results-2020-03-31
https://www.nasdaq.com/press-release/aim-immunotech-announces-further-efforts-to-establish-clinical-trials-assessing
https://www.nasdaq.com/press-release/aim-immunotechs-drug-ampligen-to-be-tested-by-japans-national-institute-of-infectious
https://www.nasdaq.com/press-release/aim-immunotech-joins-with-chinagoabroad-for-an-ampligen-china-entry-against-covid-19
https://www.nasdaq.com/press-release/aim-2020-02-18
https://www.nasdaq.com/press-release/aim-immunotechs-ceo-to-appear-live-today-on-fox-business-networks-the-claman
https://www.nasdaq.com/press-release/aim-immunotechtijiaolesanxiangyouguananpulijinr-2020-02-13
https://www.nasdaq.com/press-release/aim-immunotech-announces-completion-of-third-party-clinical-trial-using-ampligen-in
https://www.nasdaq.com/press-release/aim-immunotech-to-present-at-the-investor-summit-in-philadelphia-2019-12-11
https://www.nasdaq.com/press-release/aim-immunotech-issues-stockholder-update-and-details-its-expectations-for-2020-2019
https://www.nasdaq.com/press-release/correction%3a-aim-immunotech-provides-business-update-for-the-third-quarter-of-2019
